β-Catenin: oncogenic role and therapeutic target in cervical cancer

Bingqi Wang, Xianping Li, Lei Liu and Min Wang*

Abstract
Cervical cancer is a common and fatal malignancy of the female reproductive system. Human papillomavirus (HPV) is the primary causal agent for cervical cancer, but HPV infection alone is insufficient to cause the disease. Actually, most HPV infections are sub-clinical and cleared spontaneously by the host immune system; very few persist and eventually develop into cervical cancer. Therefore, other host or environmental alterations could also contribute to the malignant phenotype. One of the candidate co-factors is the β-catenin protein, a pivotal component of the Wnt/β-catenin signaling pathway. β-Catenin mainly implicates two major cellular activities: cell–cell adhesion and signal transduction. Recent studies have indicated that an imbalance in the structural and signaling properties of β-catenin leads to various cancers, such as cervical cancer. In this review, we will systematically summarize the role of β-catenin in cervical cancer and provide new insights into therapeutic strategies.

Keywords: β-Catenin, Cervical cancer, Cell–cell adhesion, Wnt signaling pathway

Background
Cervical cancer is among the most common female malignant tumors. In 2018, cervical cancer was the fourth diagnosed malignancy and the fourth leading cause of cancer death in women worldwide. With the development of precancerous screening methods and popularization of Human papillomavirus (HPV) vaccination programs, the morbidity and mortality of cervical cancer in high-income countries have declined. However, in low- and middle-income countries, cervical cancer continues to be a heavy burden and threatens female health [1]. Hence, a fundamental study of the molecular mechanism of cervical cancer remains imperative.

HPV has been identified as a necessary cause of cervical cancer. Based on epidemiological studies, the viral infection rate might amount to 80% in sexually active women [2]. A vital step during HPV infection is integrating viral genes into the host chromosomal DNA, which leads to unusual and uncontrolled cell growth, differentiation, and death [3]. Fortunately, most HPV infections are self-limited and cleared by the immune system within several months. Only a few people can develop persistent HPV infection and progress to cervical cancer [4]. So, exposure to HPV alone is “necessary but not sufficient” for cancer carcinogenesis; other factors, such as genetics, epigenetics, environment, immunity, and behavior, may also impact [5].

β-Catenin, the vertebrate homolog of Drosophila Armadillo, is a multifunction protein encoded by the CTNNB1 gene in humans [6]. As a member of the catenin protein family, it has a significant role in regulating and coordinating intracellular adhesion. As a critical regulator of the Wnt signaling pathway, which controls embryonic development and adult tissue homeostasis, β-catenin functions as a transcriptional activator when coupled with members of the T cell factor/lymphoid enhancer factor (TCF/LEF) family of DNA-binding proteins [7]. In normal epithelial cells, the level of cytoplasmic β-catenin is regulated, and membrane localization is observed. While in multiple cancer cells, including breast cancer [8], gastric cancer [9], bone cancer [10], colorectal...
cancer [11], and hepatocellular carcinoma [12], the cytosolic β-catenin elevates for the mutations of Wnt/β-catenin pathway core components. To date, accumulating evidence has confirmed that cervical cancer is attributed to the imbalance in the structural and signaling properties of β-catenin [5]. Yet, most pioneering work has not systematically explained how β-catenin takes part in cervical cancer. Therefore, this review will center on the growing evidence implicating in the function, regulation, and alteration of β-catenin in cervical neoplasia, to provide theoretical insights for cervical cancer prevention and therapy.

Main text

β-Catenin: structure and subcellular localization

β-Catenin is a 781-amino-acid protein and belongs to the armadillo protein families. It was initially discovered in the late 1980s as an E-cadherin-associated protein [13] and characterized in primary screening of genes required for embryonic development in Drosophila [14]. The central region of β-catenin includes 12 Armadillo (ARM) repeats, flanked by the well-defined amino-terminus domain (NTD) and carboxyl terminus domain (CTD) [15]. Between the last ARM repeat and the flexible part of the CTD is a specific conserved helix, which was essential for the signaling activity of β-catenin [16]. Each “ARM repeat” comprises a repeating 42 amino acid motif and forms three helices in a triangular shape. All “ARM repeats” form a superhelix that features a long and positively charged groove [17]. Using the core ARM domain structure, the central region of β-catenin forms a scaffold and provides an interactive platform for β-catenin binding partners. Most binding partners share overlapping binding sites, while β-catenin interacts with them in a mutually exclusive fashion. One possibility is that spatial segregation of different binding partners exerts a role in regulating its binding properties. Another explanation could be the competition among them, which is indispensable for enabling the functions of these proteins. Conformation changes in β-catenin may also be helpful [18]. Altogether, the distinct features of β-catenin depend on the structural composition of β-catenin (Fig. 1).

Cellular β-catenin exists in three different pools: membranous, cytoplasmic, and nuclear [19]. Freshly synthesized β-catenin interacts with E-cadherin and serves as a structural protein localized to the cell membrane (membranous pool). In contrast, destruction complex captures free β-catenin in the cytoplasm and rapidly targets it for degradation (cytoplasmic pool). Due to the compromised function of the destruction complex, β-catenin escapes degradation and translocates into the nucleus (nuclear pool) [19]. In different cell pools, β-catenin undergoes distinct regulation patterns and have diverse functions.

Dual functions of β-catenin

β-Catenin executes two main tasks: structural role in the adherens junctions and signaling activity in the gene transcription. These two functions are orchestrated by mechanisms, which regulate the spatial separation, retention, or stability of β-catenin.

β-Catenin: intracellular adhesion regulator

Cell–cell junctions are requisite for maintaining cell and tissue polarity and integrity. One of the cancer characteristics is defective cell–cell and cell–matrix adhesion [20]. Vertebrates comprise three intercellular junction systems: tight junction, adhesion junction, and gap junction. Among constituent structural molecules that assemble to form adhesion junctions, cadherin/catenin-based anchoring junctions organize and tether microfilaments to maintain cell adhesive properties and integrate intracellular and intercellular signaling [21]. Classical cadherins are single-pass transmembrane glycoproteins mediating calcium-dependent intracellular adhesion. They are the core of adhesion junctions and include many subtypes, such as E(epithelial)-, N(neutral)-, VE(vascular-endothelial)-, P(placental)-, R(retinal)-, and K(kidney)-cadherins [22]. E-cadherin is the primary mediator of intracellular adhesion in epithelial cells. The extracellular region of E-cadherin binds to other cadherins present on adjacent cells. Its intracellular part interacts with catenin molecules consisting of β-catenin, γ-catenin, and other regulatory proteins [23]. α-Catenin directly binds to the N-terminal region of β-catenin and thereby connects the cadherin-catenin complex to the actin filaments [24], which
promotes adhesion junction proteins clustering and stabilizes the cell adhesion (Fig. 2). Without a Wnt stimulus, the majority of β-catenin locate at the membrane. It contributes to forming the E-cadherin/β-catenin complex, building an epithelial barrier, and restricting cell invasion and metastasis [25].

**β-Catenin: transcriptional activator**

β-Catenin is a pivotal component of the canonical Wnt signaling pathway, regulating embryonic development, tissue regeneration, stem cell maintenance, and adult tissue homeostasis [26]. In the canonical Wnt pathway, the Wnt signal is the chief regulator of β-catenin. It induces the stabilization of β-catenin in the cytoplasmic pool and initiates intracellular signaling via β-catenin nuclear translocation. In the Wnt “off” state, cytosolic β-catenin is tightly regulated by a so-called β-catenin destruction complex, which comprises scaffold protein Axin, tumor suppressor adenomatous polyposis coli (APC), two kinases casein kinase 1(CK1) and glycogen synthase kinase 3β(GSK3β) [27, 28]. Upon Axin and APC recognizing free β-catenin, CK1, and GSK3β induce amino-terminal serine-threonine phosphorylation of β-catenin [29], making β-catenin for ubiquitination dependent proteolysis [30]. In the Wnt “on” state, Wnt glycoproteins bind to Frizzled (FZD) and low-density lipoprotein receptor-related protein (LRP), thereby recruiting the disheveled (DVL) to the cell membrane [31]. Resultant FZD-LRP-DVL polymers then induce the docking of Axin and reassemble the destruction complex [32, 33]. β-Catenin accumulates in the cytoplasm and translocates into the nucleus where it displaces Groucho from TCF/LEF and activates the transcription of downstream genes such as cyclin-D1, c-Myc, Axin 2 (Fig. 3) [34].

Interestingly, accumulated evidence has verified that the disruption of the E-cadherin/β-catenin complex affects not only the intracellular adhesion but also the canonical Wnt pathway. Many target genes of Wnt canonical cascade, such as Twist and Slug, could also influence cadherin adhesion [35]. Therefore, cadherin loss and increased β-catenin signaling, which are attributed to imbalanced dual functions of β-catenin, can cooperate to induce both carcinoma and development.

### Regulation of β-catenin functions through phosphorylation

β-Catenin executes two main functions in epithelial cells. The degree to which β-catenin participates in both roles is regulated through phosphorylation by various kinases (Table 1). This phosphorylation regulatory mechanism modulates the binding affinity of β-catenin and promotes the controlled formation of protein–protein interactions [36]. Here, we only discuss the essential phosphorylation sites.

**Phosphorylation of β-catenin at the membrane**

Phosphorylation of β-catenin at the membrane often leads to a weakening of the E-cadherin/β-catenin complex [37]. Two tyrosine residues in β-catenin have received the most attention: tyrosine 142 (Y142) in the first armadillo repeat and tyrosine 654 (Y654) in the last. Y142 is vital for α-catenin binding, and Y654 is crucial for E-cadherin. Phosphorylation at Y142 by the Fer, Fen, and c-Met tyrosine kinases diminish α-catenin binding [38]. It results in loss of binding to α-catenin and favors β-catenin binding to the nuclear transporter.
B-cell lymphoma-9 (Bcl9). Phosphorylation of Y654 by the epidermal growth factor receptor (EGFR) or Src inhibits the catenin/E-cadherin interaction. It gives rise to enhance phosphorylated β-catenin binding affinity for multiple transcription factors, for example, TATA-binding protein (TBP), CREB-binding protein (CBP), and TCF4 [39].

**Phosphorylation of β-catenin in the cytoplasm**

The significance of phosphorylation at Serine45(S45), Serine33(S33), Serine37(S37), and Threonine41(T41) sites is underscored for maintaining normal cytoplasmic β-catenin concentration. Without Wnt stimulation, β-catenin is recruited by the destruction complex. It is first phosphorylated at S45 by CK1 and then at S33, S37, and T41 by GSK3β [40]. S33 and S37 phosphorylation...
create a binding site for the β-transducin repeat-containing protein (β-TrCP) E3-ligase complex, leading to ubiquitination and rapid degradation by the 26S proteasome [41]. In contrast, Wnt signaling represses β-catenin phosphorylation, thus inducing β-catenin cytoplasmic accumulation and cytoplasmic-nuclear trafficking. Mutations at such S/T residues above might hamper β-catenin function and have been described in human colorectal cancer and several other malignancies.

**Phosphorylation of β-catenin in the nucleus**

β-Catenin does not possess any DNA-binding domain, so it functions by interacting with other DNA binding transcription co-factors. Previous findings demonstrated that phosphorylation of β-catenin might modulate the recruitment of these factors. β-Catenin Y142 phosphorylation by c-Met promotes Bcl9-2 binding, which acts as co-activators in Wnt signaling [39]. Protein kinase B (AKT) and Protein kinase A (PKA) phosphorylate β-catenin at residues S552 and S675 and strengthen β-catenin/TCF reporter activation, possibly through association with histone acetylase [42, 43]. Phosphorylation of β-catenin at S663 by PKAL regulates its transcriptional activity and induces target gene expression [43].

**Interaction between HPV and β-catenin**

Unlike other cancers, persistent infection of HPV plays a unique role in cervical carcinogenesis. There are three events during HPV infection as cancer promoters: viral DNA integrates to host genome, viral oncoproteins (E6 and E7) express in the epithelial cells, and viral oncoproteins interact with cellular proteins [50]. The well-known oncogenic model is that E6/E7 binds and inactivates the tumor suppressor proteins p53 and retinoblastoma protein (pRb), respectively, interrupting cell-cycle control and initiating gene transcription [51]. E6 and E7 interact with a plethora of cellular proteins involved in cell signaling that participate in the establishment of the malignant phenotype, including β-catenin (Table 2).

Lichtig et al. demonstrated for the first time that HPV 16 E6 enhances β-catenin/TCF transcription in an E6 associated protein(E6AP)-dependent manner, providing a possible mechanistic link between HPV and the β-catenin signaling in cervical cancer cell lines [52]. Sominsky et al. proposed that E6/E6AP stimulates and augments Wnt signaling through different mechanisms. The Wnt-stimulatory function requires the activity of E6AP and GSK3β [53]. Recent investigations have made it evident that HPV E6 is related to the Forkhead box protein M1 (FOXM1), which interacts with β-catenin and activates the Wnt pathway in mammalian cells [54]. In E6-expressing cells, E6 induces Myeloid zinc finger 1 (MZF1) expression, and MZF1 activates NK2 homeobox 1 (NKX2-1) transcription. The promoter of FOXM1 harbors three putative sites for NKX2-1. Thus E6 upregulates FOXM1, activates the Wnt/β-catenin pathway, and initiates cancer carcinogenesis through the E6/MZF1/NKX2-1/FOXM1/β-catenin transcriptional factors axis [55]. We found part of the evidence in the interaction between E6 and proteins harboring PDZ domains. Disks large homolog 1(Dlg1) and Scribble contain PDZ domains and interact with APC. E6 targets Dlg1 and Scribble, leading to their degradation [52]. HPV-induced loss of p53 may contribute to aberrant β-catenin expression in cancers [56]. The ubiquitin ligase type 3 Siah-1 binds ubiquitin-conjugating enzymes and Ebi, acts as β-TrCP, and results in β-catenin degradation independent of the phosphorylation sites recognized by β-TrCP. P53 and DNA damage activate the Siah-1/SIP/Ebi-dependent pathway for β-catenin destruction. Other studies of GSK3β indicated that HPV 16 E6/E7 increases GSK3β transcripts through a region between 85 bp and 250 bp upstream of the transcription initiation site of human GSK3β gene, which in turn modulates cellular β-catenin [57]. The impact of the E7 in regulating Wnt signaling has not been studied as well as that of E6. In the double-transgenic mice model, co-expression of HPV 16 E7 and a constitutively active β-catenin could accelerate cervical carcinogenesis [58].

### Table 2 Interactions between HPV oncoproteins and β-catenin in Wnt signaling

| HPV oncoproteins | Interactions                                      | Biological effects                                                                 |
|------------------|--------------------------------------------------|-------------------------------------------------------------------------------------|
| E6              | E6-E6AP-β-catenin                                | Blocks proteasomal degradation of β-catenin and promotes its translocation to the nucleus |
|                  | E6-Dlg2/Scribble-APC-β-catenin                   | Inactivates APC and leads to β-catenin nuclear accumulation through E6-induced degradation of the Dlg1 and Scribble |
|                  | E6-MZF1/NKX2-1/FOXM1-β-catenin                    | Induces MZF1 expression and then activates NKX2-1 transcription, finally promotes FOXM1-mediated β-catenin nuclear translocation |
|                  | E6-p53-Siah-1/SIP/Ebi-β-catenin                   | E6-induced loss of p53 inactivates Siah-1/SIP/Ebi complex, which can act as β-TrCP and lead to β-catenin degradation |
| E7              | E7-PP2A-β-catenin                                 | Binds to both the catalytic and structural subunits of PP2A and consequently induces Wnt activa- |
phosphatase 2 (PP2A), a family of multimeric serine/threonine phosphatases, is also involved in the β-catenin degradation complex. PP2A directly interacts with APC and Axin, dephosphorylates S9 residue of GSK3β, and ultimately inhibits Wnt signaling. In the human keratinocytes model immortalized by HPV E6 and E7 oncoproteins and transformed with SV40 small T antigen (smt), Uren et al. discovered that smt directly inactivates PP2A, which leads to β-catenin accumulation [59]. Other findings suggested HPV 16 E7 binds to both the catalytic and structural subunits of PP2A and, consequently, induces Wnt activation [60].

With the previous evidence, HPV oncoproteins directly or indirectly interact with β-catenin, subsequently activate β-catenin signaling, and finally promote cervical carcinogenesis. Thus, HPV may be the initial hit in the multistep tumorigenesis, alterations of β-catenin and hyperactivation of the Wnt/β-catenin pathway in cervical cancer cells serve as a second hit to accomplish the development of cervical cancer.

The oncogenic role of β-catenin in cervical carcinogenesis

The role of β-catenin in the initiation of cervical cancer

In various types of cancer, deregulation of the Wnt/β-catenin signaling pathway occurs almost invariably via mutations in APC gene, dysfunction of GSK3β, or mutations of β-catenin itself [61]. However, in cervical cancer tissue or cancer-derived cell lines, mutations in Wnt pathway members, such as CTNNB1, have rarely been detected [20, 62]. We posit that occasional variations in CTNNB1 accompany β-catenin abnormal expression in cervical cancer, but it is accomplished by employing upstream β-catenin regulators. Some proteins contribute to this process either directly or indirectly. In vitro and in vivo analyses showed that transcription factor AP-2β interacts with β-catenin through the DNA-binding domain of AP-2β and the 1-9 Armadillo repeats of β-catenin. AP-2β forms a complex with β-TrCP and β-catenin, thereby enhancing β-catenin degradation independent of the proteasome degradation system [63]. Li et al. confirmed that SRY-related HMG-box 17 (SOX17), a member of the SOX transcription factor family, binds to the region between −1756 and −1473 of β-catenin and trans-suppresses β-catenin in cervical cancer cells, resulting in downregulation of β-catenin target genes and inhibition of tumor formation [64]. The Dickkopf 3 (Dkk3) protein was significantly downregulated and showed a strong regulation of β-catenin in cervical cancer cells. Though Dkk3 indirectly binds to β-catenin, it could interact with β-TrCP, enhance the degradation of cytoplasmic β-catenin, and lead to its anti-proliferative activity [65]. Leucine-rich repeats containing G protein-coupled receptors 5 (LGR5) was also found to regulate β-catenin in human cervical cancer indirectly. The possible mechanism is that LGR5 recruits the LRP-FZD receptor complex and reinforces Wnt signaling following the phosphorylation of LRP, ultimately induces LGR5-mediated promotion of cervical cancer growth via the Wnt/β-catenin signaling pathway [66]. Li et al. suggested that Dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1 (DAX1) may bind to the site of −T222 to −444 of GSK3β promoter and transcriptionally repress GSK3β in cervical cancer cell lines. Therefore, DAX1 promotes cancer cell growth and tumorigenicity by allowing β-catenin to escape degradation via GSK3β [67]. Wang et al. reported that the expression level of Na+/H+ exchanger regulating factor 1 (NHERF1) is reduced significantly in cervical cancer tissues. NHERF1 regulates β-catenin protein levels in HeLa and CaSki cells. It may attenuate β-catenin expression via suppression of α-actinin-4 (ACTN4) expression and inhibit cervical cancer cell proliferation via the NHERF1-ACTN4-β-catenin axis [68].

The roles of non-coding RNAs should also be valued. MicroRNAs (miRs) are a class of non-coding RNAs with ~20 to 22 nucleotides in length and negatively regulate the expression of various cancer-related genes by binding to 3′-untranslated regions (UTRs) [69]. Recent studies have suggested that miR-135a regulates β-catenin expression through abating Siah1 and possibly APC in the presence of high-risk HPV E6/E7 [70]. Wei et al. proposed that the overexpression of miR-638 inhibits the Wnt/β-catenin signaling pathway and correlates with the prognosis of cervical cancer patients [71]. Ji X’s team has demonstrated that miR-139 targets and inhibits TCF4, the critical transcription factor cooperates with β-catenin to activate the downstream target genes in response to Wnt signals. MiR-139 thereby significantly blocks β-catenin signaling and decreases cell proliferation in cervical cancer cells [72]. Li et al. reported that miR-378 targets the 3′-UTR of the suppression of tumorigenicity 7 like (ST7L) mRNA and affects the regulation of Wnt/β-catenin pathway [73]. ST7L is a tumor-suppressor gene and inactivates the Wnt/β-catenin pathway in various cancers [74]. Long non-coding RNAs (LncRNAs) are a class of single-stranded RNAs, more than 200 nucleotides (nt) long, which are incapable of coding proteins. LINCO0675 expression causes a significant increase of β-catenin, and LINCO0675 knock-down increases the phosphorylation of β-catenin, which causes degradation of β-catenin in the cytoplasm and nucleus. LINCO0675 may affect Wnt/β-catenin signaling in cervical cancer and represent a potential diagnostic marker and therapeutic target for cervical cancer treatment [75]. The luciferase assay and western blot results revealed that highly expressed long non-coding RNA NNT-AS1 activates the
β-catenin cascade and promotes cell proliferation in cervical cancer [76]. CASC11 is a newly discovered lncRNA located ~ 2.1 kb upstream of c-Myc in chromosome 8q24 gene desert. Hsu et al. indicated that CASC11 activates the Wnt signaling, upregulates the β-catenin, and promotes cervical cancer progression [77]. Other IncRNAs, for example, Bladder cancer-associated transcript 1 (BLACAT1), and Taurine upregulated 1 (TUG1), also supports cervical cancer by altering β-catenin and modulating the Wnt signaling pathway [76].

The role of β-catenin in the epithelial-mesenchymal transition of cervical cancer
As critical epithelial markers, the lack of β-catenin at the membrane promotes epithelial cells to convert to mesenchymal cells, which have been recognized as an essential process during carcinogenesis. Frequent cytoplasmic localization of β-catenin observed in cervical cancer tissue, and nuclear β-catenin expression was faint [78]. These results differ from those found for colorectal carcinoma [79], hepatocellular carcinoma [47], and prostatic cancer [80], β-catenin accumulates within the nucleus or cytoplasm. In a tissue microarray study of 147 cervical cancer cases, the impairment of E-cadherin and β-catenin expression is widespread in early-stage cervical cancers [81]. Jing et al. demonstrated that E-cadherin and β-catenin expression levels are gradually reduced with cervical cancer progression. The expression pattern of β-catenin differs on a molecular level, as the β-catenin protein level in the cell membrane declined, while its cytoplasmic expression level is upregulated [82]. Fujimoto J et al. have found that the integral expression of E-cadherin, α- and β-catenin mRNAs are suppressed in the metastatic lesions of advanced uterine cervical cancers. At the same time, it was not present in the primary tumors. Thus, the suppressed expression of main adhesion molecules might lead to invasiveness and metastatic potential of advanced uterine cervical cancers as one rate-limiting step [83]. Gregg et al. proposed that E-cadherin, α-, β-, and γ-catenin membrane location is decreased in squamous cell cancer compared to normal cervical epithelium. It’s associated with increased metastatic potential due to the loss of intercellular adhesion function and cell polarity related to epithelial-mesenchymal transition (EMT) [84]. A large number of experiments have verified the abnormal expression pattern of β-catenin in cervical cancer cells, so what are the factors that caused the ectopic expression of β-catenin? Experimental data confirmed that the Wnt antagonists Secreted Frizzled Related Protein 1 (SFRP1) and Wnt antagonists Secreted Frizzled Related Protein 2 (SFRP2) suppress the EMT of cervical cancer through Wnt signaling [85]. He et al. observed that S100A9 induces cell migration and EMT, while the S100A9-induced promotion of EMT significantly suppressed by downregulation of β-catenin [86]. Combined in vitro and in vivo research found that miR-4524b regulates the migration and invasion ability of cervical cancer by targeting Wilms’ tumor X protein (WTX), and WTX regulates the expression of β-catenin [87]. The inhibitor of β-catenin and TCF (ICAT) acts as a Wnt/β-catenin signaling pathway suppressor via blocking the binding of TCF to β-catenin. Jiang et al. confirmed that overexpressed ICAT promotes cervical cancer EMT by competing for the E-cadherin binding to β-catenin, thus disrupting the E-cadherin/β-catenin complex [88]. Zhang et al. indicated that cysteine-rich protein 1 (CRIP1) upregulates the mesenchymal markers vimentin and N-cadherin, elevates cytoplasmic β-catenin expression, and downregulates the epithelial molecule—E-cadherin. The present study revealed that CRIP1 is concerned with the aberrant Wnt/β-catenin signaling pathway and promotes migration and invasion of cervical cancer [89].

The role of β-catenin in chemo-/radio-therapy resistance
Primary or secondary resistance to chemotherapy or radiotherapy results in treatment failure. The molecular mechanisms involved in chemo-radiotherapy resistance are complex. Accumulating evidence has found that β-catenin may participate in these molecular pathways. Zhang et al. observed that the nuclear localization of β-catenin is a poor prognostic marker and correlated with chemo-/radio-resistance in cervical squamous cell cancer [90]. Zhou’s study uncovered an indispensable role of Fat mass and obesity-associated gene (FTO). Indeed, these parameters could regulate the expression of β-catenin by reducing m6A levels in its mRNA transcripts and enhance the chemo-radiotherapy resistance in cervical cancer [91]. The previous study conducted by Wang et al. showed that the expression of Peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 (Pin 1) displays resistance to cisplatin in five cervical cell lines. They implied that Pin1 modulates chemo-resistance by upregulating FOXM1 expression and the Wnt/β-catenin signaling pathway involved [92]. Xu et al. suggested that chemotheraphy activates β-catenin signaling in an eukaryotic initiation factor 4E (eIF4E)-dependent manner. Blocking of eIF4E or β-catenin sensitizes cervical cancer to chemotherapy [93]. Cytosolic phospholipase A2α (cPLA2α), a predominant source of arachidonic acid, is specifically upregulated in cervical cancer. The inhibition of cPLA2α significantly increases chemosensitivity in cervical cancer cells, and this process has been proved to act in a β-catenin-dependent manner. In addition to being directly associated with cervical cancer development, β-catenin also mediates cell resistance to drugs.
and reduces the therapeutic effect [94]. Therefore, targeting β-catenin may have therapeutic value in overcoming chemo-/radio- resistance in cervical cancer.

Clinical value of β-catenin in cervical cancer therapy
In addition to being considered a potential prognostic biomarker, β-catenin is also a vital molecular-target in cervical cancer therapy. Imura et al. assessed the prognostic influence of β-catenin by immunohistochemistry in cervical cancer patients. In this multivariate analysis, the low pathologic stage (stages I and II) and preservation of β-catenin expression is independently favorable prognostic factors [95]. Liang et al. found a negative association between WIF1 expression and β-catenin in 196 cervical cancer patients, 39 cervical intraepithelial neoplasia (CIN) patients, and 41 normal cervical epithelium (NCE) subjects. β-Catenin serves as a poor prognostic marker for cervical cancer [96]. Jiang et al. examined the expression of the representative EMT markers (β-catenin and E-cadherin) in normal cervical tissue, CIN1, CIN2-3, and squamous cervical cancer and found the expression of β-catenin reduces gradually during the progression of cervical squamous cell lesions. Patients with squamous cervical cancer with lymph node metastasis, parametrial invasion, negative E-cadherin, and negative β-catenin expression has shorter overall survival and disease-free survival [82]. Besides, nuclear β-catenin expression is related to chemo-resistance and radio-resistance in cervical cancer [90].

Several approaches for targeting β-catenin, which include enzyme inhibitors, β-catenin/TCF antagonists, and transcriptional regulators, have been developed. For example, a small-molecule MSAB directly targets β-catenin at Armadillo repeat region 2 and inactivates oncogenic β-catenin signaling [97]. Tankyrase inhibitors, like XAV939 [98], K-756 [99], and WXL-8 [100], stimulate β-catenin degradation by stabilizing Axin. PKF115-584 and CFP049090 are examples that perturb the β-catenin/TCF complex in a dose-dependent but non-selective manner [101]. The nonsteroidal anti-inflammatory drugs (aspirin and indomethacin) modulate TCF activity and attenuate the β-catenin signaling [102]. Additionally, other compounds (CRT3/iCRT5/iCRT14/BC21/BC23/HI-B1) have been reported to suppress tumor growth via inhibiting β-catenin-TCF4 interaction [103–106]. PRI-724 is a first-in-class small molecule antagonist that inhibits the interaction between β-catenin and its transcriptional co-activator CBP [107]. Some compounds mentioned above have already progressed to phase II oncology trials [108], but some are still under the discovery phase. Presently, no drugs, specifically inhibiting β-catenin, have been approved for the market [109]. Though β-catenin is a potentially druggable target, the possibility of adverse side effects cannot be ignored; it will require more detailed studies to address the key issue of the specificity of β-catenin inhibitor.

Conclusion
To sum up, β-catenin is a kind of multifunctional protein-encoding by CTNNB1. In epithelial, β-catenin regulates epithelial cell growth and intracellular adhesion. In the Wnt signaling pathway, it is a crucial effector controlled by Wnt proteins and modulates transcription of genes. The Wnt signaling and phosphorylation systems regulate the switch between β-catenin’s adhesive and nuclear translocation functions. Different forms (phosphorylated vs. non-phosphorylated) have different effects on carcinogenesis and tumor progression. It has become definite that β-catenin contributes to cervical cancer through accumulating experimental evidence. It has effects on promoting cell proliferation, mediating EMT, enhancing cell resistance to chemo-/radio-therapy. The alterations of β-catenin itself, disruption of E-cadherin/β-catenin complex, and molecules directly or indirectly impacting the abnormal expression of β-catenin may contribute to this progression. A more accurate perception of the β-catenin precise regulatory mechanism in cervical cancer carcinogenesis is still needed to conduct in the future. For instance, further studies could focus on the genetic mutations and epigenetic alterations of CTNNB1 in cervical cancer, the relationship between other HR-HPV oncoproteins or different HPV subtypes, and β-catenin, the precise biomolecules-β-catenin binding mechanisms. β-Catenin is a potential prognosis biomarker and a druggable target for cancer therapy. More profound research of β-catenin useful for diagnosis, treatment, and prognosis of cervical cancer in larger samples and multicenter settings is worth exploring.
Acknowledgements
Not applicable.

Authors’ contributions
The head group leader MW was responsible for the article conceptualization; BW and LL performed the research investigation; BW was responsible for the original writing; MM and XL contributed for reviewing and editing; MW supervised the work. All authors read and approved the final manuscript.

Funding
This study was supported by the Natural Science Foundation of Hunan Province [Nos. 2019JJ40426, 2019JJ40418].

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
ince [Nos. 2019JJ40426, 2019JJ40418].

Funding
vised the work. All authors read and approved the final manuscript.

Wang et al. Biol Res (2020) 53:33

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.
3. Doorbar J. Papillomavirus life cycle organization and biomarker selection. Dis Markers. 2007;23(4):297–313.
4. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Cancer. 1993;12(2):186–92.
5. Perez-Plasencia C, Duenas-Gonzalez A, Alatorre-Tavera B. Second hit in cervical carcinogenesis process: involvement of wnt/beta catenin pathway. Int Arch Med. 2008;1(1):10.
6. Barth AL, Nathke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol. 1997;9(5):683–90.
7. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1998;275(5307):1787–90.
8. Khamtsvor A, Khamtsvo GF, Trettakova M, Hau D, Olopade OI, Goss KH. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010;176(6):2911–20.
9. Wang S, Tian Y, Wu D, Zhu H, Luo D, Gong W, et al. Genetic variation of EMT induced by TGF-beta, SHH, and WNT and their crosstalks. J Clin Med. 2016;5:4.
10. Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene. 1999;18(55):7860–72.
11. Schwarz-Romond T, Fiedler M, Shibata N, Butler PJ, Kikuchi A, Higuchi Y, et al. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol. 2007;14(6):484–92.
12. Lecarpentier Y, Claes V, Vallee A, Hebert JL. Thermodynamics in cancers: opposing interactions between PPAR gamma and the canonical/WNT/beta-catenin pathway. Clin Transl Med. 2017;6(1):14.
13. Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, et al. E-Cadherin/beta-catenin complex and the epithelial barrier. J Biomed Biotechnol. 2011;2011:567305.
14. Roua S, Miravet S, Piedra J, de Herreros A, Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem. 1999;274(5):36734–40.
15. Tominaiga J, Fukunaga Y, Abeleardo E, Nagauchi A. Defining the function of beta-catenin tyrosine phosphorylation in cadherin-mediated cell-cell adhesion. Genes Cells. 2008;13(1):67–77.
16. Piedra J, Martinez D, Castano J, Miravet S, Dunach M, de Herreros AG. Regulation of beta-catenin structure and activity by tyrosine phosphorylation. J Biol Chem. 2001;276(23):20436–43.
17. Dalgery RL, Gottiert CJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda). 2007;22:303–9.
18. MacDonald BT, Tamaki K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26.
19. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Dev Cell. 2002;16(9):1056–76.
20. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hamerschmidt M, Birchmeier W. Essential role of BCL9.2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev. 2004;18(18):2225–30.
43. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem. 2006;281(15):9971–6.

44. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282(15):11221–9.

45. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/diphosphorylation of beta-catenin. Curr Opin Cell Biol. 2005;17(3):459–66.

46. Du C, Zhang C, Li Z, Biswas MH, Balaji KC. Beta-catenin phosphorylated at threonine 120 antagonizes generation of active beta-catenin by spatial localization in trans-Golgi network. PLoS ONE. 2012;7(4):e33380.

47. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol. 1999;55(5):703–10.

48. Hart M, Cormondet JP, Lassot I, Albert I, Santos R, Durand H, et al. The F-box protein beta-TCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol. 1999;9(4):207–10.

49. Park MH, Kim DJ, You ST, Lee CS, Park SM, et al. Phosphorylation of beta-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun. 2012;419(3):543–9.

50. Ho GT, Berman R, Beardslie L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–8.

51. Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.

52. Lichtig H, Gilboa DA, Jackman A, Gonen P, Levav-Cohen Y, Haupt Y, et al. HPV16 E6 augments Wnt signaling in an E6AP-dependent manner. Virology. 2010;396(1):147–57.

53. Sominsky S, Kuslansky Y, Shapiro B, Jackman A, Haupt Y, Rosin-Arbesfeld R, et al. HPV16 E6 and E6AP differentially cooperate to stimulate or augment Wnt signaling. Virology. 2014;468–470:510–23.

54. Gong A, Huang S. FoxM1 and Wnt/beta-catenin signaling in glioma stem cells. Cancer Res. 2012;72(22):5658–62.

55. Chen PM, Cheng YW, Wang YC, Wu TC, Chen CY, Lee H. Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis. Neoplasia. 2014;16(11):961–71.

56. Matsuzawa S, Reed JC, Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell. 2001;7(5):915–26.

57. Ma C, Zeng C, Jin L, Yang Y, Li P, Chen L, et al. GSK3beta mediates the carcinogenic effect of HPV16 in cervical cancer. Sci Rep. 2015;5:16555.

58. Bulut G, Fallon S, Beauchamp EM, Drebbing LE, Sun J, Berry DL, et al. Beta-catenin accelerates human papilloma virus type 16-mediated cervical carcinogenesis in transgenic mice. PLoS ONE. 2011;6(11):e27243.

59. Uren A, Fallon S, Yuan T, Husubuton A, Kucukali T, Schlegel R, et al. Activation of the canonical Wnt pathway during genetic keratinocyte transformation: a model for cervical cancer progression. Tumour Biol. 2005;26(4):1619–20.

60. Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene. 2005;24(33):7830–8.

61. Webster MT, Rozycka M, Sara E, Davis E, Smalley M, Young N, et al. Sequence variants of the axin gene in breast, colon, and other cancers: an analysis of mutations that interfere with GSK3 binding. Genes Chromosomes Cancer. 2002;30(4):443–53.

62. Shinohara A, Yokoyama Y, Yan X, Takahashi Y, Mori Y, Takami T, et al. Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix. Gynecol Oncol. 2001;82(3):450–5.

63. Wang F, Huang W, Hu X, Chen C, Li X, Qiu J, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog. 2017;56(8):1909–23.

64. Li L, Yang WT, Zheng PS, Liu XF. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/beta-catenin signaling pathway via trans-suppressing beta-catenin in cervical cancer. Cell Death Dis. 2018;9(7):741.
pathway. Int J Oncol. 2019;55(1):35–44.
87. Li T, Zhou W, Li Y, Gan Y, Peng Y, Xiao Q, et al. MiR-4524b-5p/WTX/beta-
catenin axis functions as a regulator of metastasis in cervical cancer. PLoS ONE. 2019;14(4):e0214622.
88. Jiang Y, Ren W, Wang W, Xia J, Gou L, Liu M, et al. Inhibitor of beta-
catenin and TCF (ICAT) promotes cervical cancer growth and metastasis by disrupting E-cadherin/beta-catenin complex. Oncol Rep. 2017;38(5):2597–606.
89. Zhang LZ, Huang LL, Huang AL, Liu JX, Yang F. CRIP1 promotes cell migration, invasion and epithelial-mesenchymal transition of cervical cancer by activating the Wnt/beta-catenin signalling pathway. Life Sci. 2018;207:420–7.
90. Zhang Y, Liu B, Zhao Q, Hou T, Huang X. Nuclear localization of beta-catenin is associated with poor survival and chemo-/radioresistance in human cervical squamous cell cancer. Int J Clin Exp Pathol. 2014;7(7):3908–17.
91. Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R, Wang YY, et al. FTO regulates the epithelial–mesenchymal transition and activating the Wnt/beta-catenin pathway. Int J Oncol. 2019;55(1):35–44.
92. Wang T, Liu Z, Shi F, Wang J. Pin1 modulates chemo-resistance by up-
regulating FoxM1 and the involvements of Wnt/beta-catenin signaling pathway in cervical cancer. Mol Cell Biochem. 2016;413(1–2):179–87.
93. Xu H, Wang Z, Xu L, Mo G, Duan G, Wang Y, et al. Targeting the elf4e/beta-
catenin axis sensitizes cervical carcinoma squamous cells to chemotherapy. Am J Transl Res. 2017;9(3):1203–12.
94. Xu H, Sun Y, Zeng L, Li Y, Hu S, He S, et al. Inhibition of cytosolic phospholipase A2 alpha increases chemosensitivity in cervical carcinom through suppressing beta-catenin signaling. Cancer Biol Ther. 2019;20(6):912–21.
95. Imura J, Ichikawa K, Takeda J, Fujimori T. Beta-catenin expression as a prognostic indicator in cervical adenocarcinoma. Int J Mol Med. 2001;8(4):353–8.
96. Liang J, Zhou H, Peng Y, Xie X, Li R, Liu Y, et al. beta-Catenin expression negatively correlates with WIF1 and predicts poor clinical outcomes in patients with cervical cancer. Biomed Res Int. 2016;2016:4923903.
97. Hwang SY, Deng X, Byun S, Lee C, Lee SJ, Suh H, et al. Direct targeting of beta-Catenin by a small molecule stimulates proteasomal degradation and suppresses oncogenic Wnt/beta-Catenin signaling. Cell Rep. 2016;16(1):28–36.
98. Huang SM, Mishina YM, Liu S, Cheung A, Stegemeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614–20.
99. Okada-Iwasaki R, Takahashi Y, Watanabe Y, Ishida H, Saito J, Nakai R, et al. The discovery and characterization of K-756, a Novel Wnt/b-Catenin pathway inhibitor targeting Tankyrase. Mol Cancer Ther. 2016;15(7):1525–34.
100. Ma L, Wang X, Jia T, Wei W, Chu M, Su S. Tankyrase inhibitors attenuate WNT/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget. 2015;6(28):25390–401.
101. Lepourcelet M, Chen YN, France DS, Wang H, Crews P, Petersen F, et al. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004;5(1):91–102.
102. Dihlmann S, Siemann A, von Knebel Doeberitz M. The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-
catenin/TCF-4 signaling. Oncogene. 2001;20(5):645–53.
103. Gonsalves FC, Klein K, Carson BB, Kats S, Ekan LA, Evans S, et al. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc Natl Acad Sci USA. 2011;108(15):5954–63.
104. Tian W, Han X, Yan M, Xu Y, Duggigeni S, Lin N, et al. Structure-based discovery of a novel inhibitor targeting the beta-catenin/TCF4 interaction. Biochemistry. 2012;51(2):724–31.
105. Zhang Q, Gao M, Luo G, Han X, Bao W, Cheng Y, et al. Enhancement of radiation sensitivity in lung cancer cells by a novel small molecule inhibitor that targets the beta-Catenin/TCF4 interaction. PLoS ONE. 2016;11(3):e0152407.
106. Shin SH, Lim DY, Reddy K, Malakhova M, Liu F, Wang T, et al. A small molec-
eucle inhibitor of the beta-Catenin/TCF4 interaction suppresses colorectal cancer growth in vitro and in vivo. EBioMedicine. 2017;25:22–31.
107. Fischer MM, Cancilla B, Yeung VP, Cattaruzzo F, Charter C, Muriel CL, et al. WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Sci Adv. 2017;3(6):e1700090.
108. Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–64.
109. Cui C, Zhou X, Zhang W, Qu Y, Ke X. Is beta-catenin a druggable target for cancer therapy? Trends Biochem Sci. 2018;43(8):623–34.
110. Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting β-catenin phosphorylation in the nucleus. J Biol Chem. 2009;284(5):3323–33.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.